Cancers (Basel) 2 , 338363 (2010)
Disclosures: David Goldberg: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, Neelima Gaddipati: Nothing to Disclose, Sirisha Gaddipati: Nothing to Disclose, Yalda Zarnegarnia: Nothing to Disclose, Peter Reese: Nothing to Disclose, Catherine Blandon: Bluebird Bio: Stock - publicly traded company, Intellia Therapeutics: Stock - publicly traded company, Editas Medicine: Stock - publicly traded company 2640 THREE-DIMENSIONAL MR ELASTOGRAPHY PREDICTS CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH CIRRHOSIS: A PROSPECTIVE MULTICENTER STUDY Yu Shi 1 He Zhu 2 Meng Niu 1 Jie Chen 3 Bo Wei 3 Bin Song 3 Zhenghan Yang 4 Hui Xu 4 Dawei Yang 4 Jingjing Liu 5 Yong Zhang 5 Jingliang Cheng 5 Xiaolong Qi 6 , 1 China Medical University, 2 The Sixth Peoples Hospital of Shenyang, 3 Sichuan University West China Hospital, 4 Beijing Friendship Hospital, 5 First Hospital of Zhengzhou University, 6 Zhongda Hospital, Southeast University Background: To explore a Three-dimensional MR elastography (3D-MRE) model for noninvasive diagnosis of clinically significant portal hypertension (CSPH, HVPG10mmHg) and severe portal hypertension (SPH, HVPG12mmHg) in cirrhosis, using hepatic venous pressure gradient (HVPG) as the gold standard
United Nations (2012)
Nevertheless, Rogan is obsessed
